Literature DB >> 30894410

Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice.

Leslie M Randall1, Michael J Birrer2, Thomas J Herzog3.   

Abstract

Staying current on the rapidly evolving therapeutic landscape in oncology is challenging for clinicians. This commentary discusses exciting practice‐changing data specific to ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30894410      PMCID： PMC6516122          DOI： 10.1634/theoncologist.2019-0020

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  30 in total

1.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Authors:  Eric Pujade-Lauraine; Felix Hilpert; Béatrice Weber; Alexander Reuss; Andres Poveda; Gunnar Kristensen; Roberto Sorio; Ignace Vergote; Petronella Witteveen; Aristotelis Bamias; Deolinda Pereira; Pauline Wimberger; Ana Oaknin; Mansoor Raza Mirza; Philippe Follana; David Bollag; Isabelle Ray-Coquard
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

Review 2.  Bevacizumab toxicities and their management in ovarian cancer.

Authors:  Leslie M Randall; Bradley J Monk
Journal:  Gynecol Oncol       Date:  2010-04-02       Impact factor: 5.482

3.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Carol Aghajanian; Stephanie V Blank; Barbara A Goff; Patricia L Judson; Michael G Teneriello; Amreen Husain; Mika A Sovak; Jing Yi; Lawrence R Nycum
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

4.  Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  Bradley J Monk; Helen Q Huang; Robert A Burger; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Sharon X Liang; Lari Wenzel
Journal:  Gynecol Oncol       Date:  2012-12-04       Impact factor: 5.482

5.  Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.

Authors:  Maurie Markman; P Y Liu; Sharon Wilczynski; Bradley Monk; Larry J Copeland; Ronald D Alvarez; Caroline Jiang; David Alberts
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

6.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro
Journal:  N Engl J Med       Date:  2018-10-21       Impact factor: 91.245

7.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

Authors:  Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Euan Macpherson; Claire Watkins; James Carmichael; Ursula Matulonis
Journal:  N Engl J Med       Date:  2012-03-27       Impact factor: 91.245

8.  Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.

Authors:  Jonathan A Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Bryan Bennett; David Parry; Stuart Spencer; Helen Mann; Ursula Matulonis
Journal:  Br J Cancer       Date:  2016-11-08       Impact factor: 7.640

9.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Robert L Coleman; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Jesus Garcia-Donas; Elizabeth M Swisher; Anne Floquet; Gottfried E Konecny; Iain A McNeish; Clare L Scott; Terri Cameron; Lara Maloney; Jeff Isaacson; Sandra Goble; Caroline Grace; Thomas C Harding; Mitch Raponi; James Sun; Kevin K Lin; Heidi Giordano; Jonathan A Ledermann
Journal:  Lancet       Date:  2017-09-12       Impact factor: 79.321

10.  The role of secondary surgery in recurrent ovarian cancer.

Authors:  D Lorusso; M Mancini; R Di Rocco; R Fontanelli; F Raspagliesi
Journal:  Int J Surg Oncol       Date:  2012-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.